THERAPEUTIC TARGETING OF MEVALONATE PATHWAY IN ARID1A-MUTATED OVARIAN CANCER

$1,093,800FY2022Defense Health AgencyDOD

The Univeristy Of Texas M.D. Anderson Cancer Center

Investigators